• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention concerns novel 4-phenyl-1,3-dioxan-5-ylalkenoic acid derivatives of the formula I having cis relative stereochemistry at positions 4 and 5 of the dioxane ring and wherein Ra and Rb are variously hydrogen, alkyl, halogenoalkyl, alkenyl, and optionally substituted aryl or arylalkyl, Rc is hydroxy, alkoxy or alkanesulphonamido, n is 1 or 2, A is ethylene or vinylene, Y is (2-5C)polymethylene optionally substituted by alkyl, and benzene ring B is optionally substituted phenyl, or, when Rc is hydroxy, a salt thereof. The acid derivatives antagonise one or more of the actions of thromboxane A2 (TXA2) and are expected to be of value in those disease conditions in which TXA2 is involved. The invention also provides pharmaceutical compositions containing an acid derivative of formula I, and processes for their chemical production.
    公开号:SU1277893A3
    申请号:SU833596399
    申请日:1983-05-11
    公开日:1986-12-15
    发明作者:Джордж Брюстер Эндрю；Колкетт Родни
    申请人:Империал Кемикал Индастриз,Плс (Фирма)；
    IPC主号:
    专利说明:

    solvents or diluents at a temperature of from -70 ° C to room temperature and the desired product S1I is isolated and the compound of the formula 1 where R j is hydroxy is converted to the compound of formula 1 where RC C is Cg; 1H is sulfonamone; al cannsulfonamide in the presence of a dehydrating agent, and / or a compound of formula I, where A is vinylene, is converted to a compound of formula I, where A is ethylene, by hydrogenation in the presence of a catalyst and in the case when it is necessary to obtain an optically active form of the compound of formula I, The optically active 3 starting compound or the racemic form of the compound of formula 1, where K is an O-active group, is reacted with the optically active form of the organic base, followed by separation of the resulting diastereoisomeric salt mixture and the optically active form of the compound of formula 1 followed by treatment with an acid or R - hydroxy group, converted to a compound of formula I, where R, is a C.-Cg-alkoxy group, by esterification with an appropriate acid ;, or a compound of formula 1, where K is hydroxy, translated to physi Environmentally acceptable salt with a base.
    The invention relates to a process for the preparation of new compounds - derived from 4-phenyl-1,3 dioxane-cis-5-ylalkenoic acid or their optically active forms, or their physiologically acceptable salts with bases. These compounds have the ability to inhibit one or more of the actions of thromboxane A2 (TXA2) and are valuable therapeutic agents.
    The aim of the invention is to detect in a series of 4-substituted 1., 3-dioxan-5-ylalkenic acids a novel biologically active property.
    In the following examples, the evaporation operations are carried out on a rotary evaporator in a vacuum; the manipulations are carried out at room temperature (826 ° C); approximately 50-70 g of SiOj per 1 g of sample are used in chromatographic columns (kieselgap 60, Merck, ref. 7734), the process is followed by thin-layer chromatography on Merck plates (kieselhal 60 F.254, art. 5715), FJI-chrome mapping is carried out on Merck's firm core (art. 9385); NMG spectra are usually determined at a frequency of 90 MHz in CDC1, using tetrametry1C1shan (TMS) as an internal standard, with a single chemical shift value for the multigshot (m) given, this corresponds to the center point of the signal constituting the multiplet; all end products are isolated in the racemates; those compounds of formula 1, in which A- is a vinylene radical, may contain 3-5% by weight of stereoisomeric form E.
    An example. (2,2-Dimethyl-4-phenyl-1, 3-dioxane-qi; 5-yl) acetaldehyde.
    2.0 g is added in argon with stirring and chilled by ice to a solution of ylide prepared from (4-carboxybutyl) triphenylphosphonium bromide (1.25 g) and dimsiline
     (5.4 g) in 150 cells of dimethyl sulfoxide and the mixture is stirred overnight. With careful addition of 200 ml of water, followed by extraction with ether (3 times 150 ml), remove
    V is the mass of the neutral material; the aqueous elephant is acidified to pH 5-6 with aqueous oxalic acid. Upon subsequent extraction with ether, drying with sodium sulfate and evaporation, the crude product is obtained as a yellow-yellow oil. When chromatographed on a column with elution with a mixture of toluene: ethyl acetate: acetic acid (80: 20: 2 by volume), 5 (Z) -7- (2 ,, 2-dimethyl 4-phenyl-1 5 3-dioxane-cis) are obtained 5-yl) heptenoic acid in the form of an oil (i., 8 g), which solidifies to give the substance with m. 76-78 ° C.
    NMR spectrum, ppm: 1.55 (6H, s.); 5 1.3-2.6 (9H, m.); 3.7-4.3 (W, m.); 5.1-5.5 (GP, m.); 7.3 (5H, br.s.); 9.59 (1H, p.). The source material was prepared as follows. A solution of 10 g of ethyl 2-al1Sl-3-oxo-3-phenylpropionic acid in 20 ml of dry tetrahydrofuran is added over 5 minutes to a suspension of 2 g of lithium aluminum hydride in 130 ml of tetrahydrofuran in argon with stirring at 2-78 ° C. Cm-fO the si is allowed to warm to room temperature, stirred for 6 hours and then treated with 25 ml of ethyl acetate and too MP of a saturated aqueous solution of ammonium chloride. Filtration, extraction of the aqueous phase with ether (three times 150 ml), drying the ether layer with sodium sulfate and evaporation give 10 g light brown of oil. When the mixture is chromatographed and eluted with CHY chloroform: ethyl acetate (9: 1 by volume), 5.4 g of 2-allyl-1-phenyl-1, 3-propanediol are obtained in the form of a colorless oil. NMR spectrum: 1.6-2.2 (ZN, m.); 3.0 (IE, s.); 7.3 (5H, br.s.). A solution of 5.4 g of 2-aplyl-1-phenyl-1,3 propanediol in 2,2-dimethoxypropane (250 ml) is treated with p-toluenesulfonic acid (25 mg) and left overnight at room temperature. While adding 5 drops of triethylamine with a brown oil is obtained by subsequent blending, which after flash chromatography on a column of silica gel (30 g per 1 g of sample) and elution with a mixture of toluene: hexane (1: 1 by volume) gives 2.1 g (4.5-cis) 5- allyl-2,2-dimethyl-4-phenyl-1,3-dioxane as a colorless oil, which solidifies to give a substance with mp. 41-43 ° C and NMR spectrum: 1.55 (6H, s.); 1.2-1.6 (ЗН, m.); 3.8-4.2 (2H, m.); 4.8-5.9 (ЗН, m.); 5.2 (1H, d, J 2.7 Hz); 7.3 (5H, br.s.) and (4,5-trans) -5-allyl-2,2-dimethylg-4-phenyl-1,3-dioxane as a colorless oil (1.8 g) which hardens giving substance with so pl. 31-34 ° C and NMR spectrum, MD: 1.4 (3N, p.); 1.5 (MN, s.); 1.3-2.2 (ЗН, m.); 3.54, 0 (2H, m.); 4.5 (1H, d, J Q Hz) 4.7-5.8 (3N, m); 7.3 (5H, br.s.). Through a solution of 2.1 g of (4,5-cis) -5allyl-2, 2-dimethyl-4-fekyl-1,3-dioxane 200 ml of methylene chloride, ozone is passed in until a clear blue tigor blue of para-heptenic acid is formed as a colorless oils with a yield of 45%.
    NMR spectrum, MD: 0.7-1.2 (bN, m.); 1.3-2.6 (13H, m.); 3.7-4.3 C2H, m.); sewing The solution was flushed with argon until the gure decolorized. A solution of 2.1 g of triphosphate phosphine in 40 ml of dichloromethane is added and the mixture is allowed to warm to room temperature. When evaporated with subsequent chromatography on a column with elution with a mixture of chloroform: ethyl acetate (19: 1 by volume), 2.0 g (2,2-dimethyl-4-phenyl1, 3-dioxane-1C1s-5-yl) acetaldehyde are obtained in the form white solid, mp, 67-69 ° C, NMR spectrum, MD: 1.55 (6H, s.); 2.0-3.1 (ЗН, m.); 3.7-4.4 (2H, m.); 5.2 (t, d, J 2.0 Hz); 7.3 (5H, broad s.) Example 2. Diazomet-n is distilled into a solution of 320 mg of 5 (Z) -7- (2,2-dimethyl-4-phenyl-1, 3-dioxane-cis-5-yl) heptenoic acid in 10 ml of dry ether with ice cooling until the mixture acquires a stable yellow-green color. Add a solution of acetic acid in ether (10 vol.%) until the hiss ceases. The mixture is concentrated, diluted with 20 MP of carbon tetrachloride, provided with activated bone charcoal at room temperature and evaporated to give 5 (Z) -7- (2, 2-dimethyl-4-phenyl-1, 3-dioxane-cis-5-) methyl ester or a) heptenoic acid as a colorless oil (300 mg). NMR spectrum, MD: 1.5 (6H, p.); , 4 (9H, m.); 3.65 (ZN, p.); 3.74, 3 (2H, m.); 5.2 (ZN, M.) V 7.3 (ZN, p.); m / e 332 (molecular ion), Example 3. Example 1 is carried out as follows, except that methyl (4-carboxypentyl) triphenol phosphonium is used instead of methyl (4-carboxybutyryl) triphenylphosphonium bromide and 2.2 g of 6 (Z) are obtained. -8 (2,2-dimesh1-A-phenyl-1,3-dioxane-cis5-yl) octanoic acid as a colorless oil. NMR spectrum, ppm: 1.5 (6H, s.); 1.2-3.5 (MO, m.); 3.7-4.3 (2H, m.); 7.3 (5H, m.); m / e 404 (M, trimethylsil il). Example 4. The procedure is as in Example 1, but starting from (2,2-ethyl-4-fench1-1, 3-dioxane-cis-5-yl) acetaldehyde, 5 (Z) -7- (2,255 diethyl-4 -fensh1-1, Z-dioxane-cis-5-yl) 51 5.1-3.5 (3N, m); 7.3 (5H, br.s.); m / e 347 C + I) n 317 (, m - ethyl). The starting material was obtained as follows. A solution of 20 g of (4,5-cis) -5-allyl-2,2 dimethyl-4-phenyl-1,3-dioxane and 400 ml of tetrahydrofuran is treated with a solution of hydrochloric acid (2 M, 10 ml) in 100 ml of water and the resulting solution is heated reflux to boiling for 3 hours. The mixture is evaporated. The resulting brown oil is dissolved in ethyl acetate (200 ml). This solution was washed; 1 dt with water (3 times 100 ml each), dried with sodium sulfate and evaporated to give 17 crude erythro-2-allyl-1-phenyl1, 3g propanediol as a colorless oil, which is used without further purification. A solution of crude erythro-2-all-1-1-phenyl-1, 3-propyl-1 (17 g) in 200 ml of toluene, containing 10 g of 3-pentanone and 50 mg of para-toluenesulfonic acid, was boiled under reflux cooling with NIKOM for 4 hours using the Dean trap and stark to remove water. The reaction mixture is diluted with 100 ml of toluene, washed with 2M aqueous sodium hydroxide solution (50 ml) and then with water (100 ml), dried with sodium sulfate and evaporated to give a brown oil, which upon chromatography on a column and elution with toluene gives 5.8 g ( 4,5-cis-5-allyl-2,2-diethyl-4-phenyl-2,3 dioxane as a colorless oil. Nuclear Magnetic Resonance Spectrum, M.D .: 0.7-1.2 (6H, .m); 1.4-2.6 (7H, 1m); 3.7-4.3 (2H, m) 4.7-5, U (3N, m); 5.2 (N, d, J ZHz); 7.3 (5H, m). Through a solution of 5.8 g of (4,5-cis) -5allyl-2, 2-diethyl-4-phenyl-1,3-dioxane in 600 ml of dichloromethane with -JS, ozone is passed in until a constant blue is formed. staining solution. The solution is flushed with argon until bleaching. A solution of 7.5 g of triphenylphosphine in 150 ml of dichloromethane is then added and the mixture is stirred at -20 ° C overnight and for 3 hours at room temperature. The mixture is evaporated and the residue is purified by chromatography on a column, eluting with a mixture of chloroform and ethyl acetate (19: 1 by volume), to give 4.3 g (2,2-diethyl-4-fench 1-1,3-d oxane cis-5-yl) -acetaldehyde. in nida colorless oil. NMR spectrum, 27 36 MD: 0.7-1.2 (bu, m); 1.6-3.0 (7H, m); 3.6-4.4, 5.2 (1H, d, J 2.4 Hz); 7.3 (5H, pshr. S); 9.5 (W, s). Example 5, In the same way. as in the example. 1, but starting from (2,2dimethyl-4- (2 methylphenyl-1,3 dioxanthis-5-yl) acetaldehyde, it turned out 5 (E) -7-2,2-dimethyl-4- (2-meTylfensch 11, W- dioxan-cis-5-yl) heptenoic acid in the form of a white solid (0.69 g), mp 72-75 ° C. NMR spectrum: 1.55 (6H, s); 2.3 (3N , c); 1.3-2.7 (9H, m); 3.7-4.3 (2H, m); 5.0-5.6 (W, m); 7.1-7.6 (4Y, m); m / e 333 (molecular ion + H). The starting material is obtained in the form of an oil using a technique similar to that described in Example 1. NMR spectrum, ppm: 1.5 (3N, s); 1.6 (ZI, s); 1.82, 9 (ZN, m); 2.4 (ZN, s); 3.6-4.2 (2H, m); 4.9 (W, d, J 9 Hz); 7.17, 6 (4H, m); 9.45 (IE, s). Starting from 2-allyl-3- (2-methylphenyl) -3-oxopro ethyl ester . Ionovoj acid which was obtained as an oil dissolved Vschel following intermediates analogous to those of Example 1: a) 2-allyl-1 (2-methylphenyl) -1,3propandiol as a colorless oil. NMR spectrum, MD: 1.6-2.6 (ZN, m); 2.3 (3N, s); 3.7 (2H, d); 4.8-6.0 (4H, m.); 7.0-7.7 (4H, m); b) (4,) - 5-allyl-2,2-dimethyl4- (2-methylphenyl) -1, 3-dioxane with elution with chloroform: ethyl acetate (19: 1 by volume) 200 mg (4-phenyl1, 3- dioxan-1-5-yl) acetaldehyde as a colorless oil. NMR spectrum, MD: 2.1-3.2 (3N, m); 4.1 (2H, m) j 4.9-5.4 (ZN, m); 7.3 (5H, broad s); 9.6 (1H, width, s). Example 6. A solution of 500 mg of 3 (2, 2-d11methyl-4-phenyl-1, 3-dioxane-cis5-yl) propionic1dehyde in 5 ml of dry hydrogen methyl sulfoxide was added under an atmosphere of argon under ice cooling to a stirred solution of the ylide prepared from 2, 4 g of methyl (4-carboxypropyl) triphenylphosphonium and 1.2 g of sodium disyl in 20 ml of dry dimethyl pulpulfoxide. The mixture is stirred for 18 hours. 50 ml of water are added and the aqueous mixture is extracted with ether (3 times 50 ml each time) to remove a mass of neutral material. The aqueous layer was acidified to pH 5-6 (2M hydrochloric acid) and extracted with ether (4 times 50 ml). The combined extracts are dried with sodium sulfate and evaporated. The residual yellow oil is purified on a chromatographic column, eluting with toluene: ethyl acetate: acetic acid (80: 20: 2 by volume) to give 300 mg of 4 (g) -7- (2,2-dimethyl- 4phenyl-1, 3-dioxane-dis-5-yl) heptenoic acid as an oil. NMR spectrum MD: 1.5 (6H, s); 1.3-2.6 (1H, m); 3.7-4.3 (2H, m); 4.9-5.4 (3N, m); 7.3 (5H, br.s.); m / e 191, 107 and 91 The starting material is prepared as follows. The borane solution is added to a stirred cooled solution of (4, cis) -5-allyl-2,2-dimethyl-4-phenyl-1, dioxane (2.32 g) in dry tetrahydrofuran (50 ml) under argon atmosphere. Stirring is continued for 30 minutes and the mixture is sequentially treated with an aqueous solution of sodium hydroxide (20 ml) and 30% hydrogen peroxide solution (5 ml). After another 30 min, add 100 ml of brine and extract the mixture with ethyl acetate (3 times 70 ml). The extracts are dried with sodium sulfate and evaporated to give 2.6 g of 3- (2,2-dimethyl4-phenyl-1, 3-dioxane-cis-5-yl) -1-propanol (B) as a colorless oil, which is used without further cleaning up. A suspension of pyridinium chlorochromate (1.62 g) in 25 ml of dichloromethane is treated with solution B (1.25 g) in 10 ml of dichloromethane. Mix over 40 min. 100 ml of ether are then added and the solution is drunk through a short column containing activated magnesium silicate (25 g, 60-100 mesh. The column is carefully eluted with ether and the eluate is evaporated. The residual oil is purified on a chromatographic column, eluted with chloroform: ethyl acetate (9: 1 by volume) to obtain 3 (2,2-dimethyl-4-phenyl-1,3-dioxane-cis 5-yl) -propionaldehyde as a colorless oil (550 mg). NMR spectrum, MD: 1.55 (6H, s); 1.2-2.3 (5H, m); 3.7-4.3 (2H, m); 5.2 (IH, brs); 7.3 (5H, brs ); 9.55 (1H, s). Examples 7-19. Using a technique similar to that described in Example 1, but starting from the corresponding aldehyde of formula II () and the ylide from (4-carboxybutyl) triphenyl phosphonium bromide, receive compounds of formula IB (R-R -metsh j, shown in Table 1. 38} necessary 1n: course)) aldegs of formula II (R - R | -methyl,) is obtained in 56-95% yields from the corresponding derivatives of formula IV (R and methyl) in the same manner as described in Example 1, starting from the corresponding 2-allyl-3- (substituted phenyl) -3- ethyl ethyl ester oxopropionic acid (see tab. I). These aldehydes have properties listed in Table. 2. Intermediate (4,5-cis) 5-allyl-2, 2-dimethyl-4-phenyl-1,3-dioxanes (any isomeric (4,5-trans) 5-allyl-2, 2-dimesh -4-phenyl-1,3-dioxane is removed by chromatography), which are presented in table. 3. Derivatives of 5-allyl-1,3-dioxane are obtained by cyclization of erythro-forge of the corresponding 2-allyl-1- (substituted phenyl) -1,3-propanediol in the presence of 2,2-dimethoxypropane by analogy with the method of example 1. Necessary erythro -diols are obtained together with the corresponding threo-diols in the form of oils, by reducing lithium aluminum hydride or lithium borohydride 2-all-1-sh-3- (substituted phenyl) -3-oxopropionic acid ethyl ester and using them without purification and determination of parameters. Erythro-diol can be obtained practically without the admixture of a threo isomer by means of a two-stage reduction, initially using zinc borohydride, then using lithium aluminum hydride. The latter procedure is exemplified by the preparation of erythro-2-allyl1- (2,6-difluorophenyl) -I, 3-propanediol. 1. Add a solution of 1.7 g of anhydrous zinc chloride in 20 ml of anhydrous ether to a stirred suspension of 1.1 g of sodium borohydride in 401 lp of anhydrous ether, and the mixture is stirred for 18 hours. The solid is removed by filtration. A solution of 1.4 g of ethyl 2-allyl-3- (2,6-difluorophenyl) -3 oxopropionic acid ethyl ester in 10 ml of anhydrous ether is then added to the (b) filtrate cooled to 0 ° C over 5 minutes. The mixture is then stirred 45 min at 0 ° C. Then 2M hydrochloric acid is added until the evolution of gas ceases. The organic phase is separated, washed with brine, dried with magnesium sulfate and evaporated. 1.3 g of an oil is obtained, which is purified by the method
    9 27789
    Sieve chromatographic chromatography on a 40 g column of ilnagel using ethanol acetate (15 v / v) as a eluent in an ether ether (b.p.) gives 40 mg of ethyl sprit-2-allyl-3- (2,6 -difluorophenyl) -3-hydroxypropionic acid (A) in the form of a masa.
    NMR spectrum, MD: 1.02 (ZI, t); 2.58 (3N, m); 3.12 (1H, m); 3, 90 (2H, 10 k); 5.13 (ЗН, m); 5.83 (1H, m); 6.83 (2H, m); 7.24 (1H, m).
    2) A solution of ester A (340 mg) in 10 ml of anhydrous ether is added under nitrogen atmosphere for 15–3 minutes to a stirred suspension of 120 mg of lithium aluminum hydride in 30 ml of anhydrous ether at. The mixture was heated under reflux for 30 minutes and cooled with ice water. 2 ml of ethyl acetate in 10 ml of anhydrous ether and then 25 ml of a saturated solution of ammonium chloride are added over 20 hours. The resulting mixture was separated by filtration. The organic phase is washed with brine, dried over magnesium sulfate and evaporated to give erythro-2-allyl-1 (2,6-difluorophenyl) -, 3-propandiol as an oil (, 252 mg). NMR spectrum, ppm: 2.30 (5H, 30 M) J 3.60 (2H, d); 3.18 (ЗН, m); 5.9 (1H, m); 6.95 (2H, m); 7.30 (1H, m).
    The procedure with lithium borohydride is illustrated by the preparation of 2 - allyl-1 (2-ethylphenyl) -, 3-propanediol. 35
    A solution of 2-allyl-3-oxopropionate (7.3 g) in dry tetrahydrofuran (THF, 40 ml) is added over 10 minutes to a stirred suspension of lithium borohydride (1.32 g) in 40 ml of 40 dry tetrahydrofural at 0 ° C in nitrogen atmosphere. The mixture is then stirred at {} and room temperature for 18 hours, cooled to 0-5 ° C and 40 ml of water is added. The aqueous mixture is acidified to pH 45 2 (concentrated hydrochloric acid) and extracted with ethyl acetate (3 times 120 ml). The combined extracts are washed with brine, dried over magnesium sulfate and evaporated. The residual oil (6.1 g) is purified by chromatography on 180 g of silica gel using a mixture of 3: 7 (by volume) ethyl acetate and petroleum ether (b.p. 60-80 ° C), and 55% is obtained. - (2-ethylphenyl) -propane1, 3-diol (contains erythro-- and treofor a11 approximately in the ratio 4: 1) in the form of oil (4 g). NMR spectrum
    3IO
    MD: 1.19 (ЗН, m); 2.04 1.5H, m); 2.59 (2H, m); 3.76 (2H, m); 5.02 (ЗН m); 5.67 (1H, m); 7.17 (ЗН, m); 7.47 (1H, m).
    The starting 2-allyl-3 ethyl ester (splenic phenyl) -3-oxopropionic acid of formula I (R-ethyl) is obtained in the form of an oil by allying the corresponding 3- (substituted fenH) -3-oxopropion using the general method of Marvel and Hager. Examples of complex the esters of the formula V thus obtained are those in which the benzene ring B is 2-chloro, 3-chloro, 3-fluoro, 2-methoxy, 2-isoproxy, 2 trifluoromethyl, 3-trifluoromethyl and 4-methylphenyl. Source 3-oxopropionates are required, prepared using one of the following methods.
    A. The interaction of a suitably substituted benzoyl chloride with malonic acid tert-butyl ethyl ester and magnesium ethylate gives the corresponding malonic acid 2-substituted benzoyl ethyl ester, which is then hydrolyzed at 100 ° C under vacuum in the presence of para-toluenesulfonic acid (for example , those oxopropionates in which the benzene ring B is 2-chloro, 2-methoxy, 2-isopropyl and 2-trifluoromethylphenyl).
    B. Interaction of an appropriately substituted benzoyl chloride with a dilithium salt of monoethyl magnesium sulfate (obtained from two molar equivalents of butyl lithium in hexane at -70 ° C) at -65 ° C, followed by acidification with concomitant decarboxylation at room temperature (for example, those H-oxopropionates, in which the benzene ring B is 3-fluoro, 3-chloro, 3 is trifluoromethyl and 4-methylphenyl group).
    The starting 2-allyl-3- (substituted phenyl) -3-oxopropionates of the formula V (Rethyl) can be prepared from a t-butyl ethyl ethyl ester.
    (V)
    one.  to a stirred solution of 37.6 g of malonic acid tert-butyl ethyl ester in 100 ml of dry dimethylformamides, 28 - carbonate 1 I1 and potassium is added.  After 1 hour, 34 ml of allyl bromide was added.  The mixture is heated at 70 ° C for 66 hours, cooled to room temperature and diluted with water (900 ml).  The resulting mixture is extracted with ethyl acetate (3 times 200 ml).  The extracts are dried with magnesium sulfate and evaporated.  The resulting oil is purified on a column by flash chromatography, eluting with a mixture (1:15 by volume) of ethyl acetate and petroleum ether (t. kip  60-80 ° C), and get tert-butyl-ethyl ester of 2-allylmalonic acid as a colorless oil (15.6 g), t. gsh  70-72 ° C / 0.2 mmHg Art.  NMR spectrum, m d. : 1.21 (ЗН, t); 1.42 (9H, s); 2.66 (2H, m); 3.28 (1H, m); 4.16 (2H, q); 5.06 (2H m); 5.76 (W, m).  2 Sodium hydride (2.8 g, 50 wt. % dispersion in mineral oil) is added over a period of 15 minutes to an ice-cooled solution of 2-allylmalonic acid’s tert-butyl ethyl ester (13.4 g) in 120 ml of dry dimethylformamide under a nitrogen atmosphere.  The mixture is stirred at room temperature for 45 minutes and cooled to 0 ° C.  10.1 g of 2-ethylbenzoyl chloride are added in 2 minutes, the mixture is stirred at room temperature for 18 h.  The dimethylformamide is evaporated, the residue is shaken with 100 ml of water and 200 ml of ethyl acetate.  The ethyl acetate phase is separated, washed with brine, dried over magnesium sulfate and evaporated.  The resulting oil (21.8 g) is purified on a column of 650 g of silica gel using flash chromatography using toluene as eluent to give 2-allyl-2- (2-ethylbenzoyl) malonic acid t-butyl ethyl ester (14, 3 g) in the form of oil.  NMR spectrum, M. D. : 1.25 (15H, m); 2.7 (2H, q); 2.9 (2H, d); 4.12 (2H, q); 5.31 (2H, m); 6.05 (1H, m); 7.35 (4H m).  3 A mixture of 14.3 g of tert-butyl ethyl ester of 2-allyl-2- (2-ethylben zoyl) malonic acid, 4 ml of acetic anhydride and 100 mg of p-toluenesulfonic acid in 200 ml of acetic acid is heated at 140 ° C. under nitrogen for 75 minutes and then evaporated.  The residue was shaken with a mixture of 100 ml in a saturated sodium bicarbonate solution and I00 ml ethyl acetate.  The organic phase is dried with magnesium sulfate and evaporated, nony4eiifioe oil (9.3 g) 312 ooze.  (lash chromatography H. I column (280 g) using toluoog as an eluent gave 7.4 g of this 2-allyl-3- (2-eth1shpeNYL) -3-oxoproxypropanoic acid ester as a light yellow oil.  NMR spectrum, M. D. : 1.19 (6H, m); 2.74 (4H, m); 4.15 (ЗН, m); 5.05 (2H, m); 5.79 (1H, m); 7.30 (ЗН, m); 7.61 (N, m).  In addition, similar procedures are used to prepare 2-allyl-3- (2,6-difluorophenyl) 3-oxopropionic acid ethyl ester, obtained in the form of an oil - NMR spectrum, m. d. : 1,2 (ЗН, t); 2.70 (2H, m); 4.17 (ЗН, m); 4.92 (2H, m); 5.73 (1H, m); 6.95 (2H, m); 7.26 (1H, m) and 2-allyl-3- (2-fluorophenyl) -3-oxo propionic acid ethyl ester obtained in the form of an oil - NMR spectrum, m. d. : 1.23 (ЗН, t); 2.67 (2H, m); 4.20 (ЗН, m); 5.04 (2H, m); 5.83 (1H, m); 7.09 (2H, M) J 7.37 (1H, m); 7.73 (1H, m).  The NMR spectra for other representatives of 2-allyl-3-oxopropionates of the formula V (R-ethyl) obtained in the form of oils by direct sodium ethoxylate allylation of the corresponding ethyl ester (3-substituted phenyl) -3-oxopropionic acid: ethyl 2-allyl 3- (2-trifetormethylphenyl) -3-oxopropionic acid - NMR spectrum, m d. : 1.21 (ЗН, m); 2.75 (2H, m); 4.14 (ЗН, m); 5.04 (2H, m); 5.90 (W, m); 7.59 (4H, m); 2-aplyl-3- (2-chlorophenyl) -3-oxoproxyonic acid ethyl ester NMR spectrum, m. d. : 1.20 (ЗН, m); 2.71 (2H, m); 4.18 (ЗН, m); 4.93 (2H, m); 5.73 (IH, m); 7.34 (4H, m); 2-allyl-3- (2-methoxyphenyl) -3-oxopropionic acid ethyl ester, NMR spectrum, m d. : 1.17 (ЗН, m); 2.69 (2H, m); 4.10 (6H, m); 5.00 (2H, m); 5.81 (1H, m); 6.95 (2H, m); 7.38 (1H, - m); 7.51 (1H, m).  Example 20  Using a method similar to that described in prier 1, 5 (Z), 4,5-cis) 2-methyl-4-phenyl-1, 3-dioxan-5-yl heptenoic acid is obtained, yield 55 /, solid with m. square  31-32 ° C.  MR spectrum, M. D. : 1.0-2.4 (12H, m); 3.7-4.3 (2H, m); 4.7-5.0 (2H, m); 5.1-5.3 (2H, m); 7.1-7.5 (5H, m).  A melt is obtained from 2,4,5-cis) -2-methyl-4-feil-1, 3-dioxan-5-yl 3-cetapdehyde 131 and using potassium tert-butylate and tetrahydro O (5) uranium instead of sodium dimsil and dimethyl sulfoxide.  Example 21  By the same method, 5 (z) -7- (2,2-di1fOpil-4phenyl-1, 3-dioxane-cis-5-yl) -heptenoic acid is obtained, yield 60% in the form of oil, NMR spectrum, M. D. : 0.8-2.8 (23P, m); 3.6-4.3 (2H, m); 5.0-5.6 (ЗН, m); 7.1-7.6 (5H, m); 9.3 (1H,. wide with).  Prepared from (2,2-dig1prop-4phenyl-1, 3-dioxane-cis-5-yl) acetaldehyde.  The starting aldehyde for Example 21 is obtained in the form of an oil — NMR spectrum, M. D. : 1.45 (3N, d, J 5.0 Hz); 2.13, 1 (3N, m); 4.05 (2H, s); 4.7-5.1 (2H, m); 7.1-7.5 (5H, m); 9.55 (1H, s) - with a yield of 89% by oxidation of 2,4,5-cis-5-ally-L-2-methyl-4-phenyl1, 3-dioxane, which, in turn, is obtained in the form of oil - NMR spectrum, m d. : 1.45 (ZN, d, J 5.0 Hz) 1.5-2.6 (ZN, m); 3.7-4.3 (2H, m); 4.8-5.1 (4H, m); 5.3-5.8 (1H, m); 7.1-7.5 (5H, m) - with a yield of 79% by cyclization of erythroform 2-allyl1-phenyl-1, 3-propanediol with acetaldehyde, using techniques similar to those described in example 1.  The starting acetaldehyde for Example 22 is obtained in the form of an oil in 95% yield by oxidation of (4,5-cis) 5-allyl-2, 2-dipropyl-4-phenyl-1,3-dioxane using a procedure, an. illogical described in example 4.  The last dioxane, in turn, is obtained in the form of oil.  NMR spectrum, m d.  0.7-2.7 (17H, m); 3.7-4.2 (2H, m); 4.7-5.8 (4H, m); 7.0-7.4 (5H, m).  , Yield 42%.  It is obtained by the interaction of erythro-2-all-1-1-phenyl, 3-propane diol with 3-pentanone, using a technique similar to that described in example 4.  Example 22  Using a procedure similar to that described in Example 4, 5 (Z), 2-diethyl-4 (2-fluorophenyl) -1, 3-dioxane-cis-5-yl heptenoic acid is obtained with a 54% in-1 flow oils from 2, 2-diethyl-4 (2-fluorophenyl) - 1, 3-dioxane-cis-5-yl acetaldehyde.  NMR spectrum, m d. : 0, 1. 2 (6H, m); 1.3-2.6 (13H, m); 3.74. 3 (2H, m); 5.1-5.5 (ЗН, m); 7, P (3N, m); 7.52 (1H, m).  The aldehyde itself is obtained in 64% yield as an oil (absorption band in the IR spectrum e 1720 cm) by oxidation of (4,5-cis) -5-allyl-2,2-diethyl-4- (2-phenyl) -1 , 3-dioxane.  The latter compound gives significant signals in the NMR spectrum at 7.15 (3N, m) and 7.58 (1H, m), and it is obtained with a yield of 23% from erythro-2-aggill-1- (2-fluorophenyl) 1, 3 -propanediol using a technique similar to that described for the corresponding starting material in Example 4, but starting from (4,5-cis) 5-aplil-2, 2-dieth-1-4- (2-fluorofensh1) 1, 3- dioxane.  Example 23  According to a method similar to that described in Example 1, but starting from 2,2-bistrifluoromethyl-4-phenyl-1, 3-dioxane-cis-5-yl-acetaldehyde, 5 (2) -7- (2,2-bistrifluoromethyl) -4-phenyl-1, 3-dioxane-cis5 yl) heptenoic acid as a colorless oil with a yield of 65%.  NMR spectrum, M. D. : 1.3-2.6 (9H, m); 4.0-4.5 (2H, m); 4.9-5.6 (ЗН, m); 7.1-7.5 (5H, m); m / e 426 (M).  Source product is obtained in the following way.  BUT.  A solution of 15.8 g of p-toluenesulfonyl chloride in 50 ml of methylene chloride is added while moving for 2 hours to a solution of 15.4 g of crude erythro-2-allyl-1-phenyl-1,3-pronandiol in 150 ml of methylene chloride containing 12.0 ml of triethylamine, which is maintained at about 4 ° C.  The reaction mixture was stirred at 4 ° C for an additional hour, then stirred at room temperature for 64 hours, after which it was diluted with 500 ml of ether.  The resulting mixture is successively washed with water (100 ml), 5% (w / v) sodium hydrogen carbonate solution (100 ml), water (2 portions of 100 ml) and saturated brine (100 ml), then dried over sulfate magnesium and concentrate, resulting in an oil which is chromatographed on a column (eluent 10 vol. % ethyl acetate / hexane), and get 3- (spectro-2-aplil-1-phenyl-1,3-propandiol) -p-toluensulfonate (ester) (X) in the form of a colorless oil with a yield of 69%.  NMR spectrum, m d. : 1.82, 3 (4H, m); 2.4 (3N, s); 3.7-4.2 (2H, m); 4.7-5.0 (ЗН, m) j 5.35-5.8 (IB, m); 7.2-7.4 (7H, m); 7.75 (2H, d, Hz).  151 B.  3.46 g of a solution of ester (X) in 10 ml of dry ether, containing 5 mg of anhydrous p-toluenesulfonic acid, is added with stirring over 10 minutes to a solution of hexafluoroacetone prepared from 3.0 ml of sesquihydrate at -70 ° C.  The reaction mixture is stirred at -70 ° C for 2.5 hours, then allowed to rise to room temperature and stirred for an additional 16 hours.  The solvent is distilled off and the remaining oil is dissolved in 50 ml of anhydrous ether, after which 0.36 g of sodium hydride is added in portions.  The reaction mixture is stirred at reflux for 1 h, cooled and treated with 2 ml of ethanol and 50 ml of ether.  The resulting mixture was washed with water (4 portions of 15 ml), dried over magnesium sulfate and the solvent was distilled off.  After chromatography on a column. The oil obtained during the distillation (eluent 1.5 vol. % ethyl acetate / hexane) 4,5-cis-5-all-1-2,2-bis (trifluoromethyl) -4-phenyl-1,3-dioxane (VQ) is obtained as a crystalline solid (61% yield), t . square  34-35 ° C.  NMR spectrum, M. D. : 1.6-2.5 (ЗН, m); 4.1-4.5 (2H, m); 4.8-5.7 (4H, m); 7.1-7.4 (5H, m); m / e 340 (M).  AT.  Ozone is passed through a solution of dioxane (V) (1.70 g) in 100 ml of ethyl acetate at -78 s until a blue color appears.  This solution is then purged with argon until the color disappears.  A solution of 1.97 g of triphenylphosphine in 20 ml of ethyl acetate is added and the mixture is stirred at 78 ° C for 1 hour and then stirred at 4 ° C overnight.  The resulting mixture is distilled and the residue is purified by chromatography on a column using a mixture of 10 vol.% As eluent. % ethyl acetate / hexane, resulting in 2,2-bis (trifluoromethyl) -4-phenyl-1,3-dioxanes-5-ylacetaldehyde as a crystalline solid, imte c. square  52.5-53.5 ° C, with a yield of 93%.  NMR spectrum, M. D. : 2.15-3.1 (ЗН, m); 4.0-4.7 (2H, m); - 5.55 (1H, br. with); 7.15-7.55 (5H, m); 9.55 (1H, s); m / e 342 (M).  Examples 24-25.  Similarly to the method described in Example 24, 5 (Z) -7- (2,4,5cis-2-trifluoromethyl-4-fench1-1, 3-dioxan-5-yl) heptenoic acid (at 316 mer 24) is obtained in the form crystalline solid having t. gsh  87.588, 5 ° C with a yield of 76%.  NMR spectrum, M. D. : 1.2-2.7 (9H, m); 3.8-4.3 (2H, m); 4.95-5.6 (4H, m); 7.1-7.4 (5H, m); 9.25 (1H, schir. with); m / e 357 ().  5 (7) -7- (2,4-trans4, 5-cis-2-trifluoromethyl-4-phenyl-1,3-dioxan-5-yl) heptenoic acid (Example 25) is also obtained as a crystalline solid having . square  6264 ° C, with a yield of 96%.  NMR spectrum, m d. : 1.5-2.6 (9H, m); 3.85-4.5 (2H, m); 5.05-5.6 (4H, m); 7.1-7.5 (5H, m); 9.85 (W, schir. with); m / e 358 (M).  The following intermediates are obtained: 2,4,5-cis-2-trifluoromethyl-4-phenyl1, 3-dioxane-5-1-acetaldehyde as an oil in 96% yield.  NMR spectrum, m d. : 2.15-3.2 (ЗН, m); 4.0-4.2 (2H, m); 5.0-5.2 (2H, m); 7.15-7.5 (5H, m); 9.6 (1H, s); m / e 274 (m); 2,4-trans-4,5-cis-2-trifluoromethyl-4-fensch-1-1, 3-dioxane-5-acetaldehyde as a crystalline solid with m. square  62-63 ° C, with a yield of 92%.  NMR spectrum, m d. : 2.2-3.05 (ЗН, m); 3.8-4.65 (2H, m); 5.1-5.55 (2H, m); 7.15-7.5 (5H, m); 9.6 (1H, s).  These aldehydes are obtained by oxidation of the corresponding 5-allyl-1,3-dioxanes according to the method described in Example 24. These dioxanes are prepared together by replacing hexafluoroacetone with trifluoroacetaldehyde in method (b) according to Example 23, followed by chromatographic separation on silica with 2 vol.% As eluent. % mixture of ethyl acetate / hexene.  As a result of the described treatment, after separation of 2,4,5 cis-5-allyl-2-trifluoromechanes 1-4-phenyl, 3-dioxane is obtained with a yield of 49% as a crystalline solid having m. square  60-61 ° C - NMR spectrum, M. D. : 1.6-1.95 (2H, m); 2.1-2.6 (IH, m); 3.9-4.4 (2Y, m); 4.8-5.15 (4H, m); 5.3-5.8 (1H, m); 7.2-7.4 (5H, m); m / e 272 (M) and 2,4-trans-4,5-cis-5allyl-2-tri1 tormethyl-4-phenyl-1, 3ioxane in 15% yield as a crystalline solid with m. square  78-79 ° C.  NMR spectrum, m d. : 1.65-2.45 (ЗН, m); 3.9-4.5 (2H, m); , 8-5.8 (5H, m); m / e 272 (M).  Example 26  A solution containing sodium ethoxide (based on 0.095 g of metallic sodium) in 20 ml of ethanol is treated with a solution of 0.12 g of 5 (Z) -7- (2,2-di methyl-4-phenyl-1,3-dioxane -cis-5-sh1) heptanoic acid in 20 ml of ethanol, after which the reaction mixture is stirred for 2 hours.  The solvent is distilled off to obtain a white powder, which is crystallized from a mixture of dichloromethane and hexane, resulting in the sodium salt of 5 (Z) -7- (2,2-dimethyl-4-fe NHS-1, 3-dioxane-cis-5- or a) heptenoic acid in the form of white crystals having m. pl, 160-169 С (with decomposition) Results of microanalysis: Found,%: C 66.1; H 7.5.  0.50 Na + 1/4 Calculated,%; C, 66.2; H 7.4.  Examples 27-33.  A solution containing 318 mg of 5 (Z) -7- (2,2-dimethyl4-phenyl-1, 3-dioxane-cis-5-yl) heptenoic acid, 122 mg of 4-dimesh1aminopyridine and 95 mg of methanesulfonamide in 20 ml dry dichloromethane, treated with a solution of 206 mg dicyclog. Exilcarbodiimide in 2 ml of dichlorometgsha.  The resulting mixture was stirred overnight, filtered and the solvent was distilled off from the filtrate.  The remaining oil is distributed between a saturated aqueous solution of sodium carbonate (50 ml) and ether (50 ml), the aqueous phase is washed with two additional portions of ether with 25 ml each.  The aqueous phase is acidified with 2 M hydrochloric acid and extracted with 3 portions of 25 ml of ethyl acetate each.  The combined extracts are washed with saturated brine, dried over magnesium sulfate and the solvent is distilled off, to obtain an oil, which is purified by chromatography. column using toluene: ethyl acetate: acetic acid (80: 20: 2 by volume) for elution, the result is H-methanesulfonyl-5 (Z) 7- (2,2-dimethyl-4-phenyl-1,3 -dioxanzis-5-yl) heptenamide as a colorless oil (100 mg).  Spectrum 5iMP, m, d. : 1.2-2.5 (8H, m); 1.55 (6H, s); 3.25 (3N, s), 3.7-4.3 (2H, m); 5.15, 5 (3N, m); 7.1-7.4 (5H, br. with); 8.4 (1H, width  with).  Using a similar method, you can by. swallow the following N-shlcaincylnylheptenamides, based on the corresponding 1 heptheic acids of the general formula (1 b): xM-methanesulfonyl-5 (g) -7- (4-phenyl1, 3-dioxane cls-5-yl) heptamide (in the form of a solid having t. square  85-87 ° C), with a yield of 71%.  NMR spectrum, M. D. : 1.2-2.5 (9H, m); 3.25 (ЗН, s); 3.7-4.3 (2H, m); 4.8-5.5 (5H, m); 7.1-7.4 (5H, br. with); 8.4 (1H, width with); m / e 368 (H) (example 28); M-methanesulfonyl-5- (Z) -7- (2,2-diethyl-4-phenyl-1, 3-dioxane-cis-5-yl) heptenamide as an oil in 70% yield.  NMR spectrum, m d. : 0.7-1.3 (bN, m); 1.2-2.5 (13H, m); 3.25 (ЗН, s); 3.7-4.3 (2H, m); 5.1-5.5 (ЗН, m); 7.1-7.4 (5H, br. with); 8.5 (1H, width with); m / e 424 (M (- H) (Example 29); N-ethynesulfonyl-5- (Z) -7-4- (2-fluorophenyl) -2,2-dimethyl-1, 3-dioxane-cis-5-ylheptenamide in the form of oil with a yield of 77%.  NMR spectrum, m d. : 1.35 (ЗН, t); 2.15 (15H, m);  3.45 (2H, q); 4.03 (2H, m); 5.34 (ЗН, m); 7.12 (4H, m); 7.50 (1H, m); m / e: 428 (+ H) (example 30); N-ethanesulfonyl-5- (Z) -7-4- (2-ethylphenyl) -2,2-dimethyl-1,3-dioxane-cis5-ylheptanamide as an oil in 74% yield.  NMR spectrum, m d. : 1.32 (6H, n); . , 64 (8H, m); 2.33 (9H, m); 3.46 (2H, q); 4.07 (2H, m); 5.20 (ЗН, m); 7.23 (4H, m); 7.50 (2H, m); m / e 438 (M + H) (Example 31); N-mass sylfon w-5- (Z) -7-4- (2ethylphenyl) -2,3-dimethyl-1,3-dioxancis-5-ylheptenamide as an oil in 81% yield.  NMR spectrum, m d. : 1.13 (ЗН, t); 2.05 (17H, m); 3.16 (1H, s); 3.83 (2H, m); 5.15 (ЗН, m); 7.1 (4H, m); 7.37 (1H, m); m / e 424 (M + H) (Example 32) j N- (1-methylethanesulfonyl) -5- (z) -4 (2-ethylphenyl) -2. , 2-dimethyl-1, 3-dioxac G1-5-ylget enamide in the form of MA- / la with a yield of 73%.  NMR spectrum, m d. : 1.4 (15H, m); 2.27.  (1 1H, m); 3.83 (ЗН, m); 5.18 (3N, m); 7.10 (4H, m); 7.46 (1H, k). ; m / e 452 (M + H) (Example 33).  Example 34  A solution of 500 mg of 5- (Z) -7-2.4z5-cis-2-methyl-4-phenyl 5 3-dioxane-dis-5-ylheptenoic acid in 10 ml of absolute ethanol contains 100 mg of 5 wt. % palladium. on activated carbon used as a catalyst, mix at atmospheric pressure of hydrogen for 3 h.  The catalyst is separated by filtration through kieselguhr, and the solvent is distilled off from the filtrate, resulting in 5- (E) -7-2,4,5-cis 2-methyl-4-phenyl-1,3-dioxane-cis-3- heptanoic acid sludge as a colorless oil with a yield of 99%.  NMR spectrum, M. D. : 0.8-1.8 (14H, m); 2.2 (2H t, J 8 Hz); 3 8-4.25 (2H, m); 4.75 5.0 (2H, m); 7.14-7.4 (5H, m); 8.59. 3 (1H, width with); m / e 307 (M + H).  Example 34a. Using the same procedure as described in measure 34, 7- (2,2-dimethyl-4-phenyl-1, 3-dioxane-cis-5-yl) heptanoic acid can be obtained with a yield of 70-80% (after treatment in a chromatographic column using a mixture in the ratio of 80: 20: 2 by volume toluene / ethyl acetate / acetic acid as eluent) as a colorless oil NMR spectrum, M. D. : 1.55 (6H, d); 0.92. 4 (13H, m); 3.7-4.3 (2H, m); 5.15 (1H, br. with); 7.3 (5H, width with).  This is based on 5- (Z) -7- (2,2-dimetsI 4-fench1-1,3-dioxane-cis-5-yl) heptanoic acid.  The starting products are obtained by the following method.  As a result of the hydrogenation of a solution of 5- (2) -erythro-9-hydroxy-8-hydroxymethyl-9-fench1Nonenoic acid (320 mg) in 20 ml of ethyl acetate using a catalyst. Adam (30 mg) for 2 hours at atmospheric pressure, followed by filtration and distilling off the solvent; 317 mg of erythro-9-hydroxy-8-hydroxy-1-9-phenylnanoic acid is obtained as an oil, which is almost pure thin layer chromatography 4) method and is used without physical characterization. Example 35.  7.4 g of potassium t-butylate are added with stirring to a mixture of 14.7 g of 4-carboxybutyltriphenylphosphonium bromide and I70 ml of tetrahydrofuran at 0-5 ° C under nitrogen atmosphere.  The resulting mixture was added dropwise over 10 minutes while stirring to a solution of 2,2-dimethyl-4-fensch-1, 3-dioxane-cis-5-ylacetaldehyde (3.1 g) in 50 ml of tetrahydrofuran at 0-5 ° С .  The mixture is stirred for 18 hours, then poured onto 400 g of ice and the solvent is distilled off.  The aq. Residue is washed with ethyl acetate and. insoluble products are removed by filtration through diatomaceous earth.  The filtrate is cooled to 0 ° C and acidified to pH 4 by the addition of a saturated solution of sodium acid tartrate (160 ml).  The resulting emulsion is extracted with a mixture of 1.1 (by volume) ether and pentane.  The combined extracts were washed with brine, dried over sodium sulfate and the solvent was distilled off to give an oil, which was purified by column chromatography using 3: 1 (v / v) hexane and ether for the elution, to give 2.6 g of 5- (g) -7- (2,2-dimethyl-4-phenyl-1, 3-dioxane-cis-5-yl) heptenoic acid in the form of oily substance with m. square  79-85 ° C, which is crystallized from hexane 3 times to obtain the product, i.e. t. square  8686, 5 ° C.  NMR-H spectrum M. D. : 1.55 (6H, 1.4-2.7 (9H, m); 3.80 (W, double); d); 4.15 (W, width e); 5.0-5.5 (ЗН, m); 7.30 (4H, s); 11.0 (1H, shir, s).  NMR-C spectrum d.  relative to tetramethylsilane (in SCC, 22.5 Hz): 19.02 (axial CHj); 21.67 (); 24.49 (CW); 26.28 (); 29.64. (ecological CHj); 33.37 (C2); 39.66 (C5-dioxane); 62.52 (Sat-dioxane); 73.08 (C4-dioxane); 76.93 (C C); 98.98 (C2-dioxane); 125.31- (C2-phenyl); 126.72 (C4-fenne); 127.96 (Sphenyl); 128.99 (C6); 130.17 (C5); 140.80 (C1-phenyl); 179.05 (C 1, CO H) (an asterisk indicates the carbon atoms of heptenoic acid); thus, the product does not contain the 5 (E) isomer.  The starting aldehyde is obtained in the following manner.  A solution of 47 mg of osmium tetroxide in 6.0 ml of water is added with stirring to a solution of 3.6 g of 4,5-cis5-all-1-4-phenyl-1, 3-dioxane in 16 ml of tetrahydrofuran.  After the solution has turned brown (after 5 minutes), a solution of 13.7 g of potassium periodate in 90 ml of water is added dropwise to it over 30 minutes.  The reaction mixture was stirred for another 2 hours and the solids were separated by iltration.  The filter cake is passed through with hexane and the extracts in hexane are combined with the organic phase of the filtrate.  The resulting solution is concentrated in vacuo to a small volume and the resulting residue is diluted with another portion of hexane.  The resulting solution was rinsed with 10% (w / v sodium sulfide solution. , then with brine, dried over sodium sulfate and distilled off the solvent.  The residual oil after distillation is purified by column chromatography using a 1: 1 mixture (by volume of hexane and ether) for elution.  In this way, 2,2-dimethyl-4-phenyl-1,3-dioxane cis-5-ylacetaldehyde is obtained in the form of a solid product having m. square  69-70 ° C t, noc. iie recrystallization from hexane).  NMR spectrum, M. D. : 1.56 (6H, s); 2.09-2.45 (2H, m ); 2.87 UH, m); 3.80 (1H, double d); 4.33 (1H, double t); 5.24 (1I, d), 33 (5H, s), and 9.59 (1H, s).  Il and mery s 36-37.  When using a method similar to that described in Example 35, but starting from (+) - 2,2-dimethyl-4-phenyl-1,3-dioxan-5-ylacetaldehyde, (+) 5- (Z) -7- (2,2-dimethyl-4-phenyl-1,3-dioxane-cis-5-ylheptenoic acid in the form of a syrupy mass with a yield of 62%, J-99.5 ° C (s, 4.00, methanol), having An NMR spectrum identical to that described for the racemic form in Example 35, containing about 4% of the 5 (E) -isomer according to NMR-C spectroscopy.  Similarly, 5- (2) -7 (25,2-dimethyl-4-fenst-1 3-dioxane-cis-5-yl) heptenoic acid is obtained in the form of a syrupy mass with yield of 65%, oi.   (s, 4.24, methanol) J, ° having an NMR spectrum, ir; identical to that described for the racemic form in Example 35, containing approximately 5% of 5 (E) -eomer according to NMR-C 5 spectroscopy based on () 2. , 2-dimethyl - 4 phenyl-1, 3 - dioxane-11; is-5 npacet aldehyde a.  Source en. actiomeric zlyasch: iytdy get the following methods, 1.  A solution of recrystallized (1 -) - 2,2-dimethyl-4 phenyl-1 „D-dioke a n-cis 5 -yl acetal ald, é peda (14, O gt. square  69-70C) and (-) - ephedria (in 200 ml of benzene, it is heated at reflux for 2.5 hours, using a Dean-Stark apparatus for azeotropic removal of water.  Then, and 1,322 of the solution, the solvent is distilled off and the oil which is distilled off as a result of the distillation is stirred up with hexane to obtain a solid product, which is recrystallized from hexane and petroleum ether (m, kip.  30-40 ° C), resulting in (-) - 2,4,5-cis-3,4-dimethyl-2- (2,2-dimethyl-4-pheny. p-1,3-dioxancis-5-ylmethyl) -5-phenyloxazolidine (A) as a crystalline solid (5.9 g) having m. square  104105 ° C; -46 ° C, 4.23, acetone); M / e 382 (M + H).  The results of microanalysis: Found,%; C 75.5; H 8.3; N 3.7,.  Calculated,%: C 75.5; H 8.2; N 3.7.  .  2  A solution of anhydrous (+) - succinic acid (2.98 g) in 299 ml of acetone, containing 1% by volume of water, is added to a solution of (-) - enantiomer A (7.6 g) in 50 ml of acetone.  The resulting mixture was stirred for 18 hours, after which the precipitate of ephedrine tartrate was separated by filtration.  The residue is washed with acetone and the combined solution after washing and the filtrate is subjected to distillation.  The residue thus obtained is partitioned between ether and water.  The ether phase is dried over sodium sulfate and the solvent is purged.  The resulting oil is purified by column chromatography using a 3: 1 (v / v) mixture of hexane and ether for elongation} In this way, 4.3 g of (-) - (2,2-dimethyl-4-phenyl-1, , 3-dioxane-cyo-5-yl) acetaldehyxg. and in the form of a syrupy mass, o (-. p -58 ° (c: 4.20, metapol) having cr. An NMR spectrum is identical to that described in the case of the racemate of aldehyde in example 35.  3 According to the method described above (), NA, when using () ephedrine and 12.9 g of aldehyde racemate, 4.5 g of (+) - 254,5-cis 3, 4-dimethyl-2- (2.2 -dimethyl-4. phenyl i 3-dioxane-cis-5-ylmethyl) -5-phenylox3 olidine (B) in the form of crystalline t. square  104-105 С, tests, results „46 (с: 4.02, acetone); m / e 382 (К -} Н), Results of microanalysis: Found,%: С 75.9; H 8,, 0; N 3.8.  WITH. . s, 0h: Calculated,%: C 75.5; H 8. 2; four.  According to oinsatum above in section 2 method, but using (+) - succinic acid and (+) - enantiomer (B, described above) (7.9 g), I get (+) - 2.2-dimethyl-4- phenyl-1,3-dioxane cis-5-ylacetaldehyde in the form of syrupy mass (4.4 g), Co-1 +57 (c: 4.20, methanol), whose NMR spectrum is identical to the spectrum described in the case of the aldehyde racemate in example 35.  Examples 38-39.  A solution of (±) 5 - (, g) -7- (2,2-dimethyl-4-phenyl-1,3-di / oxane-cis-5-yl-) heptenoic acid (6.0 g, t. square  84-84.5C) and 1.14 g of (-) - оС-methylbenzylamine in 100 ml of ether is crystallized using salt (X) crystals as a seed (see  below).  The forming crystals are separated and collected by filtration, keeping the mother liquor (A).  The U + 45 ° crystals (c: 3.08, methanol) are recrystallized by dissolving in a minimal volume of boiling methanol, followed by the addition of 30 ml of ether per g of crystals.  After re-precipitation four times, pure salt (X) is obtained in the form of needle-like crystals (B) (1.6 g), having a constant value of the specific internal rotation fo ().  +68.8 (s: 3.14, methanol), etc. square  123-128p.  The stock solutions formed during crystallization give an additional portion of salt (X) of varying degrees of purity, oLl from +44 to +68 °, as well as their mother liquors (C).  The combined mother liquors (A) and (C) are subjected to distillation, the residue thus obtained is dissolved in a minimum amount of cold methanol.  The solution obtained is diluted with ether, washed three times with Mac-Ilvein buffer at pH 4.0, five times with water, dried over sodium sulfate and the solvent is distilled off.  The oily solid remaining after distillation (4.0 g), 1 ° (-29.9 ° (c: 3.60, methanol), was dissolved in 100 ml of ether containing 1.0 g of (+) c-methylbenzene1amine.  The resulting solution is crystallized, using as a seed salt (+) (, sy.  below).  The resulting crystals (3.2 g) c. j -55.3 (s: 3.05, methanol), separated from the solution, four times recrystallized according to the method described in the case of salt (X), resulting in a pure salt (Y) in the form of needle crystals (D) (1, 72 g) having a constant value of specific internal rotation dl ° - - -68, 7 s: 3.10, methanol) D 123-128C.  and t. Ш1.  Needle crystals (D) (1.7 g, salt Y) are dissolved in a minimum amount of methanol and diluted with ether.  Then, the resulting solution is washed three times with Mac-Ilvein buffer at pH 4.0, five times with water, dried over sodium sulfate and the solvent is distilled off.  A solution of the residue formed after distillation in 15 ml of pentane is then filtered through a silica pad (0.6 g).  The filtrate and water are combined and distilled off, the solvent gives 1.02 g of (-) - 5 (g) -7- (2,2-dimethyl-4-fench1-1, 3-dioxane-cis-5-yl ) heptanoic acid (example 38) in the form of a syrupy mass, oil -105 ° (c: 3.99, methanol).  As a result of a similar treatment of needle crystals B (1.6 g, salt X), 0.95 g of (+) - 5- (Z) 7- (2,2-dime) is obtained. Tyl-4-phenyl-1,3-dioxancis-5-yl) heptenoic acid (Example 39) as a syrupy mass, ot +106 s: 4.1 methanol), which has an NMR spectrum identical to that described in Example 35 racemate acid.  The original seed crystals are obtained by the following method.  A solution of 163 mg of (+) - acid (according to example 36) and 62 mg of (-) c -methylbenzylamine in 2 ml of ether gives 201 mg of the corresponding salt X in the form of prismatic crystals having t. square  123-128 С (not determined exactly), 0 + 67.8 ° (s: 3.17, methanol).  Similarly, from a solution of 187 mg of (-) - acid according to Example 37 and 71 mg of (+) - o {-metxbenzylamine in 3 ml of ether, the corresponding salt U is obtained in the form of prismatic crystals (22I mg) with m. square  123-128С (not determined exactly), -67.9 ° (s: 2.78, methanol).  Examples 40-41.  Using 55 1 ° Diki, similar to those described in Example 1, by replacing 2,2-dimethoxypropane with phenylacetaldehyde dimethyl acetal, 5- (E) -7- (2-benzyl-4phenyl-1, 3-dioxane-cis-5-yl) heptenoic acid is obtained (example of AO) in B1-ode of pale yellow oil, spectrum, m d. ; 1.3-2.6 (9H, m); 3.0 (2H, d); 3.77, 3 (2H, m); 4.8-5.5 (4H, m) ;, 7.3 (3N, shir. with).  Calculated,%: C, 75.79, and 7.37; Found,%: C 75.7; H 7.6, Substitution of 2,2-dimethoxypropane cyclohexairen dimethyl acetal, 5- (Z) -7- (4-phenyl-cyclohexanopyro-2-1, 3-dioxane) -dis-5-get. 11) heptoic acid (Example 41) as a colorless oil, which hardens into a material with a ton. square  76-79 ° C.  NMR spectrum M. D. : 1.3-2.7 (19H, m); 3.7-, 3 (2H, m); 5.2-5.6 (ЗН, m); 7.3 (5H, broad h); m / e 358 (M).  Examples 42-46.  A procedure similar to that of Example 1, but based on the corresponding ketone or aldehyde of the formula II R d, {, (or dimethyl) and the corresponding erythro-diol, the following compounds of the formula 1c are obtained, the benzene ring is unsubstituted; R C trimethylene; in the form of oil with a yield of 37%.  NMR spectrum, m d. : 1.3-2.7.  (15H, m); 3.7-4.1 (2H, m); 5.0 (1H, d, J 2 Hz); 5.1-5.5 (2H, m); 7.1-7.4 (5H, m); 9.9 (1H, width with); m / e 330 (M) (Example 42); R + K is hexamethylene; in the form of oil with a yield of 42%.  NMR spectrum, M. D. : 1.2-2.6 (21H, m); 3.6-4.3 (2H, m); five. 1-5.5 (ЗН, m) 7 ,, 1-7.5 (5Н, m); m / e 372 (M) (Example 43) 5 RU Rb-butyl; in the form of oil with a yield of 10%.  NMR spectrum, M. D. : 0.7-2.6.  (27H, m); 3.7-4.2 (2H, m); 5.1-5.4 (3N, m); 7.1-7.4 (5H, m) (example 44 R. d-fen1-sh, R. , -methyl; in view, oil with a yield of 40%.  NMR spectrum, m d. : 1.6 (ZN, s); 7.0-7.6 (UN, m); 7.7-8.7 (N, shir.  with); m / e - 380 (example 45) Rd-phenyl, R, -H, in the form of oil, NMR spectrum, M. D. : 1.4-2.8 (9H, m 4 ,. 1--4.3 (2H, m); 5, -5.5 (ЗН, m); 5.75 (. IH, S); 7.2-7.7 (UN, m); m / e 366 (M).  348 (), 279 (M- / SP J, CO, I), 260 (M-PhCHO).   Examples 47-75 ,, Apply a method similar to that described in measure 1, but replace benzaldehyde with a corresponding substituted aldehyde
     R, CHO, get the next 55ms, based on 1 channel instead
    acids of formula I in (benzene col-benzaldegitsa. NMR spectrum, ppm: 7,1 B is not substituted,), when used is 7.4 (5H, m) ;; 5.1-5.5 (2H, m); 4.9
    Skating shsh 10 about. methanol in chloro (5H, d, Hz); 4.75 (1H, t, J
    methylene strain, 40 vol.% acetone and-3 Hz); 3.7-4.2 (2H, m); 1.05-2.6 methylene chloride, or 40: 10: 1 (by volume) toluene / ethyl acetate / acetic acid mixture as eluent for flash chromatography (see Table 4). The starting aldehyde material for Example 75 was prepared as follows. To a solution of 1.265 g of 1,3-dihydro (5benzo / s / furyl) methanol in 1 O ml of dry methylene chloride was added 3.28 g of pyridinium dichromate in one portion. The dark mixture is stirred for 90 minutes and diluted with 100 ml of ether. The resulting suspension is separated by filtration through diatomaceous earth. The residue is taken up in ether (50 ml), the combined filtrate and evaporation solution is evaporated. The residual oil was purified by flash column chromatography, eluting with 40% v / v ethyl acetate in hexane, to give 1,3-dihydro (5-benzo / c / furyl) carboxaldehyde as a semi-solid mass (0.66 g): 9.95 (H, s); 7.7-7.8 (2H, m); 7.3 (1H, d, J 8 Hz); 5.1 (4H, s) ppm Examples 76-84. Using a procedure similar to that described for Example 30, but starting from the corresponding aldehydes of the formula RaCHO and erythro-diol VI, the following acids of the formula b are obtained with yields of 30-80%., The examples are isopropyl, R, -H, benzene colpo; in the form of butter. NMR spectrum, ppm: 10.0 (1H, brs,); 7.1-7.5 (5H, M) j 5.05, 6 (2H, m); 4.9 (1H, d, Hz); 4.5 (iH, d, Hz); 3.8-4.2 (2H, m); t, 3-2.7 (lOHjM); 1505 (6H, d, J 8 Hz); m / n (H) 331. Obtain using isobutraldehyde instead of benzaldehyde. EXAMPLE 77 R-pectyl, R, H, f The benzene ring is unsubstituted, in the form of an oil, using hexanal instead of benzaldehyde. NMR spectrum, ppm: 7.2-7.4 (5H, m); 5.2-5.5 (2H, m); 4.9 (1H, d, J 2 Hz); 4.7 flH, t, J —3 Hz); 3.7-4.2 (2H, m); 0.7-2.6 (20H, m); m / e 359 (H + K). PRI me R 78. Rj., OKTRn, P, H, benzene ring unsubstituted; in the form of (23H, m); 0.85 (ZN, t); m / e 403 (M + H). Example 79. R 2-chlorophenyl, P., H, benzene ring B is 2-fluorophenyl; in the form of oil coming from 2-chlorobenzaldehyde and 5 (Z-7-7,2-dimethyl-4 -. (2-fluorophenyl) -1 -3-dioxane-cis-5-yl heptenoic acid. NMR spectrum, M.D. .: 1.4-2.8 (9H, m); 4.1-4.3 (2H, m); 5.1-5.5 SZN, m); 6.05. (1H, s); 7.22 (7H, m); 7.82 (1H, m). EXAMPLE 80 To Co 2-methylphenyl, the benzene ring B is 2-methoxyphenyl; in the form of an oil, starting from 2-methylbenzaldehyde and 5 (Z) -7-2,2-dimethyl-4 (2-methoxyphenyl) -1, 3-dioxane-cis-5-yl; heptenoic acid. NMR spectrum, ppm: 1.4-2.8 (9H, m); 2.44 (3N, s); 3.85 (s); 4.04, 3 (2H, m); 5.1-5.5 (ЗН, m); 5.87 (1H, s); 7.28 (8H, m). PRI me R 81. Rj, methyl, benzene ring B-2-hydroxyphenyl, in the form of oil. NMR spectrum, ppm: 1.50 (bN, s 2.22 (9H, s); 2.22 (9H, m); 3.97 (2H m); 5.31 (ZN, m); 6.98 (4H, m); 8.35 (2H, s). Starting with 2,2-dimethoxypropane. EXAMPLE 82 chloromethyl, RH, benzene ring B is unsubstituted; in the form of a crystalline solid; mp 58-61 C. NMR spectrum, MD: 1.4-2.7 (9H, m); 3.65 (2H, d,); 3.85-4.3 (2H, m); 4.8 5.55 (4H, m); 7.2-7.4 (5H, m); 8.4 (1H, broad s.) Starting from 2-chloro-1,1dimethoxyethane. Dimension 83. chloroethyl, benzene ring B is unsubstituted; as a crystalline substance, mp 54-54.5 ° C. NMR spectrum, ppm: 1.4-2.6 (11H, m ); 3.75 (2H, t, J 7Hz); 3.8-4.2 (2H, m); 4.9-5.55 (4H, m); 7.2-7.4 (5H, m); 9.8 (1H, broad s.). Starting from 3-chloro-1,1-dimethoxypropane A. Example 84, H, benzene ring B, 2-methylphenyl, in the form of an oil, which crystallizes to give crystalline material, mp 83-86 ° C NMR spectrum, ppm: 7 1-7.5 (4H, m); 4.9-5.4 (5H, m); 3.8-4.1 (2H m); 1.5-2.65 (9H, m); 2.25 SZN, s). Proceeding from dimethoxymethane. The compounds of formula I are antagonists of one or more actions of TXA2, for example actions on blood platelets, on the vascular system and / or on the lungs. This antagonism can be demonstrated in one of the following tests: a) in the standard rabbit aortic band model developed by Piper and Wayne, a freshly prepared TXA2 sample generated by adding sconic acid arach (25 µg) to rabbit plasma acidified with citric acid is used as an agonist ( 250 µg), rich in platelets, allow the mixture to fully aggregate for 90 seconds before use; b) a standard test for blood platelet aggregation based on Born's description, including measuring the inhibition by the test compound of the process of aggregation of human plasma enriched with platelet-rich acidified citric acid, induced by a submaximal concentration (in the range of 25-100 µg / ml) arachidonic acid; c) a standard test for compressing the bronchi, including a measurement of the inhibition by the test compound of the compression of the bronchi induced in the Konzett-Rossler model of the Guinea Pig (modified by Collier and James) by intravenous administration of the TXA2 mimic compound and 46619 at a dose of 1.5 µg / kg. The compound of formula 1-5 (Z) -7- (2,2-dimethyl-4-phenyl-1,3-dioxane-cis-5-yl) heptenoic acid (U46619) has the following properties in the above tests: a) pA 2 6.28; b) JC, -Q around 6.7-10 M; c) reduction of bronchial contraction by 90% at a dose of 5 mg / kg intravenously. Other compounds of formula I show similar or better activity levels in test a) (pAj 5.0) and in at least one of tests b) and c) without any signs of clear toxicity with active doses in test c). Similarly, the following acid groups of the formula D show significant activity in test a) (pA, 5.9) and oral activity at a dose of 50 mg / kg (or much less) in test c) without any signs of clear toxicity. The suppression of the effect of TXA2 on the vascular system can be demonstrated as follows. Male rats (race Alderley Park) are anesthetized with sodium pentabarbntal and blood pressure is recorded in the carotid artery. A TXA2 mimicking agent, known as U 46619, for example, R, L), is administered intravenously through the strap vein and the ED () value is determined. The EDU value for U 466 19 g 7 is about 5 µg / kg. The test compound is then administered intravenously through the strap vein, or orally through cannula directly into the stomach, and the animal is monitored as a dose of U of the compound and 46619 5 minutes after the test compound is administered, and then every 10 min later until the hypertonic action and 46619 will not stop blocking. In this test, the levorotatory form of 5 (Z) - (2,2-DIETHIL-4-phenyl-1,3-dioxane-cis-5-yl) heptenoic acid showed a significant decrease (over 30%) in the hypertonic effect of the TXA2 simulator - U 46619 - within 120 minutes after oral administration at a dose of 50 mg / kg. However, the preferred compounds of formula I show a significant decrease in the hypertonic effect of U 46619, for example, at least 60 minutes after intravenous administration at a dose of 10 mg / kg or less, without any signs of obvious toxicity with an active dose. The compounds of formula I can be used to treat or prevent diseases orally, rectally, intravenously, subcutaneously, but intramuscularly or by inhalation in such a way that a dose of 0.5–20 mg / kg body weight is given to everyone once a day; depending on the condition of the patient, the weight and the age of the patient, the mode of administration of the compound is changed. The compounds of formula I can be used in the form of pharmaceutical positions, including those of the compound of formula 1 or its salt, as defined above, together with a pharmaceutically acceptable diluent or carrier. Such compositions may be in the form of tablets, capsules, solutions or suspensions for oral administration; suppositories for rectal administration; the form of sterile solutions or suspensions for intravenous or intramuscular administration as an injection; the form of aerosols or colloidal solutions or suspensions for administration by inhalation; the form of powders together with pharmaceutically acceptable solid diluents, such as lactose, for administration by injection. Tablets and capsules for oral administration can be molded using an external coating that includes, for example, cellulose acetate phthalate, to minimize contact of the active component of the formula I with acids in the stomach. In addition, pharmaceutical compositions may contain, for example, a known aggregation inhibitor , a lipid-lowering agent, an antihypertensive agent, a beta-adrenergic blocking agent, or a vasodilator for treating cardiovascular diseases or disease conditions. Similarly, an antihistamine, a steroid (such as beclomethasone dipropionate), sodium cromoglycate, a phosphodiesterase inhibitor, or a betaadrenergic stimulant can also be included in a pharmaceutical composition for use in the treatment of pulmonary diseases or conditions. The compounds of the formula D are also used as pharmacological agents in the development and standardization of test systems for evaluating the effects of TXA2 on laboratory animals (cats, dogs, rabbits, monkeys, rats and mice). The compounds of formula I can be used because of their ability to inhibit TXA2 to help maintain the viability of blood and blood vessels in warm-blooded animals (or in animal bodies) when performing artificial circulation outside the body, for example, in the process of transplantation of limbs or organs of the body. When used for these purposes, a compound of formula 1 or a physiologically acceptable salt of the compound is usually administered in such a way that its steady-state concentration in the blood is in the range of 0.550. The properties of the thromboxane antagonist for the compound of formula I are presented in Table. 5. Used a rabbit aorta plot model built
    31127789332
    Piper and Wayne. Antago Properties - The term PA2, given in Table 2, of thromboxane nysta A, is used as a measure of the antagogues of compounds of the formula of drug insanity. It is expressed as
    The values of PA2 were determined by measuring the values of pA (see Table 5).
    negative logarithm of molar 5 antagonist concentration, which reduces the effect of a double dose of an agonist, for example, thromboxane A2 or an equivalent product) to the effect of a single dose. Thus, the increased potency of the antagonist. Table 1
    58-62
    2-C1
    71-74
    2-f
    2-CF, Oil
    112-114 7.1 (4H, m)
    2-OMe
    2-Isopropyl Oil
    eleven
    Butter
    2-ETSH1
    12
    ()
    D / 68
    (SN, m)
    353 (W, m)
    )
    D / 35 (ZN, m) W, m)
    337
    (.)
    D / 38 4H, m)
    387
    ()
    T / 59
    349
    3.7 (ZN, s, OMe)
    ()
    D / 32
    361
    ()
    T / 81 347
    Notes.
    1. The NMR spectrum is determined at 90 MHz in the SDS; all spectra contain the following additional signals: 1.55 (6H, s, SC); 1.3-2.6 (9H, m, CH, CH); 3.7-4.3 (2H, m, OCHD; 5.1-5.5 (MN, m, OCHP),
    2. Bases used in the preparation of ylide: D - sodium dimsil + dimethyl sulfoxide;
    T - potassium tert-butylate n-tetrahydrofuran; B - butyl lithium + tetrahydrofuran.
    The solvent in the preparation stage is used to react the ylide with an aldehyde of formula II.
    3. DP of Example 19 ipid is added to a tetrahydrofluoric solution of aldehyde at,
    table 2
    35
    Pa 2-Isoprogyl x x 1720
    12a 2-Ethyl.XX1720
    13a 2,6-Diftor 7,12 (ZN, m) 1720
    Notes.
    1. IR spectra are usually recorded in the form of liquid films on plates of rock salt. All NMR spectra contained the following additional signals. 1.55 (6H, s, CHj); 2.0-3.1 (3N, m, CH-CH CHO); 3.7 (2H, m, OSI); 5.2, (1H, d, J 2 Hz, OCHPh).
    2. The sign X X indicates that the NMR spectra are not determined; the substance is almost pure after thin layer chromatography (TLC) on silica gel (ethylene acetate: chloroform 1: 9).
    2-Chlorine
    7.27 (ЗН, m)
    7.61 (1H, m)
    7.07 (ЗН, m)
    2-Fluorine
    7.49 (.IH, m)
    7.52 (4H, m)
    2-CF
    7, m) 2-OMe
    3, s, ohm)
    2-Isopropyl
    7.17 (ЗН, m) 2-Ethyl
    7.42 (111, m)
    - 36
    1277893 Continuation of the table. 2
    6
    Solid, so pl. 46-47 ° C
    | Table3
    38
    Butter
    Solid, mp, 77-79c
    Oil 1277893 .. 31
    , 21 (ЗН, m, 42 Me)
    2,6-Diftor
    6.95 (2H, m) 80 7.31 (1H, m)
    3-Fluorine 6.8-7.45 (4n, m) 28
    4-Methyl 7.0-7.25 t4H, 21
    2.3 (SN, s, CH)
    4-7.65 (4H, 30
    m)
    3-Chloro7.1-7.35 (4H, 26
    m)
    4-Nitro7.4-8.4 (, 4I, m) 33
    4-Fluoro6.9-7.4 (.4Н, m) 39
    Notes.
    The following signals in the HL spectrum are common to all compounds: 1.55 (6H s) 1.2-1 to 6 (3N, m); 3.8-4.2 (2H, m); 4.8-5.9 (ЗН, и); p, d, J Z, / 1c),
    Outputs: The values indicated are calculated for 2-allyl-3- (substituted phenyl) -3-oxo-propionate. The yield given for compound 146 is designed for practical clean erythro-2-all-1-1 - (2,6-difluorophenyl) -1,3-gfopavdiol and the yield for compound 116 is for a 4: 1 mixture of erythro and threo-2- allyl 1-g2-methoxyphenip) -1,3-propanediol. 38 Continued table.
    Table 4 3
    4ME-Ph
    Solid, so pl. 9395 ° C
    4N02-Ph
    Butter
    4MeO-Ph
    54
    Butter
    3Br-Ph
    55
    Butter
    56
    1-naphthyl
    Butter
    2-Naphthyl
    Solid substance so pl. 118119С
    3Me-Phenyl Oil
    59
    3.4 Clj-Ph Oil Ph
    7.0-7.5 (8H, m) 5.85 (1, s) 2.5 (3Hv s)
    380
    7.0-7.5 (9H, m) 5.65 OH, s) 2.35 (ZN, s)
    429
    8.25 (2H, d, J 8) 7.7. (2H, d, J 8) 7.25 (5H, s) 5.75 (UN, s)
    396
    7.6-8.2 (1H,)
    7.5 (2H, d, J 8.5) 7.35 (35H, s)
    6.9 (2H, d, J 8.5)
    5.6 (1H, s) 3.8 (ZN, s)
    7.15-8.2 (UN, m
    462.464 (1: 1) aromatic + CO, H)
    5.65 (W, s)
    416
    8.25 (1H, m) 8.0-7.7 (ZN, m)
    7.2-7.7 (ЗН, m, aromatic +)
    7.0-8.0 (13H, m
    416 aromatic +)
    , 85 UH, s) 7.1-7.5 (YUN, m
    380 aromatic, +)
    5.85 (1H, s)
    452, 454, 465
    7.1-8.5 (9H, m aromatic. +)
    / 4l
    1277893 Oil 7.75 (4H, s) 4CF, -Ph Oil 7.0-8.8 (YUN, m 3CF, j-Ph Oil 9.0-10.0 (1H, lgCO 3MeO-Ph Oil 8.0 -9.4 (H, 2F-Ph Oil 7.8 (1H, d, 8.2). 2MeO-Ph Oil 7.5 (4H, m) 4Bp-Ph 4CN-Ph Oil 8.0-9.2 (iH Oil 8.0-9.0 () H,
    A 2 Continued table. four
    L 5.65 (H, s) 7.3 (5H, s) 5.8 OH, c) aromatic. C0, jli) 5.75 (1H, s) broad. c) 7.05-7.5 (8H, m) 6.85 (1H, d, 5.7 (W, s) 3.8 (ZN, s) Lg) 7.75 (W, m) 6.95-7 , 5 (8H, m) 6.05 (1H, s) 7.2-7.5 (6H, m) 7.05 (W, d-t, J 1,5,8) 6.9 (1H, d, J 1.5 6.07 (1H, s) 3.85 (ZN, s) 7.2 (5H, m) 5.7 (W, s) Lg CO N / wide) 7.7 (4H, m) 7.3 ( 5H, m) 5.75 (H, s) LgCO,., H) 6.8-7.4 (9H, m) 5.7 (H, s) 34 52 96 402 396 462.464 409 384
    70
    ZNO-R
    Butter
    4AcNH-Ph
    Solid, so pl. 157159С
    72
    F.-Ph
    Butter
    uh
    73
    3,4-OSI O
    Oil-Ph
    74
    2,
    Butter
    7.5 (d, L8 / D)
    7.35 (s) -9n}
    7.25 (d, J 8)
    5.7 (1H, s)
    2.5 (ЗН, s)
    6.65-7.5 (.9Н, m) 382
    6.0-6.65 (2H, sch.c)
    8.9 (1H, lg NH) 441 7.4-7.7 (4H, m) 7.1-7.4 (5H, m) 5.65 (W, s) 2.1 (ZN, s)
    10.2-10.6 (1H, br. 456 lg)
    7.1-7.6 (5H, m) 6.1 (1H, s)
    7.2-7.4 (5H, m) 410
    7.1 (1H, lg s)
    7.05 (1H, dd, J 8.2)
    6.8 (1H, dd, J 8,2)
    5.95 (2H, s)
    5.65 (1H, s)
    7.55 (1H, d, J 8) 394
    7.2-7.4 (5H, m)
    7.05 (1H, dts. J 8,2)
    7.0 (1H, lg s)
    , 8 (IH, s)
    , 4 (ZN, s)
    , 3 (ZN, s)
    Notes.
    1. All NMR spectra were recorded in a CDSP solution at 90 MHz, with the exception of Example 60, in which the recording was made in dg-acetone. In tab. 1. Signals are given for protons of the ring B and the fragment Pa. CH, but the spectra additionally contain signals at 1.4-2.8 (9H, m), 4.1-4.3 (2H, m) and 5.1- 5.5 (MN, m) ppm The coupling constants (J) are in hertz.
    2. All mass spectra contain additional characteristic signals corresponding to the m / e M-Ra CHO; for spectra labeled C), chemical ionization was performed using ammonia, the signals correspond to m / e M + NM, not m / e M; relative ratios of isotopic values are given in brackets.
    Meme
    Meme
    Meme
    Etet
    Me .. Me
    HH
    Meme
    PhCH H
     Pentamethlen Me
    Meme
    Meme
    Meme
    Meme
    Me.me
    Meme
    Table 5
    6.28
    A B C A A A R A A A A A A L
    whine
    5.8
    5.21
    6.19
    6.49
    6.3 whines
    5.5
    6.8
    6.2
    6.08
    6,6
    5.5
    B, 01.
    6.13
    权利要求:
    Claims (1)
    [1]
    A method of obtaining derivatives of 4-phenyl-1, 3-dioxan-cis-5-ylalkenoic acid of the General formula | where R q is hydrogen, -C ^ -apkyl, unsubstituted or substituted by 1-3 halogen atoms, pentafluorophenyl, benzyl, naphthyl, phenyl, unsubstituted or substituted by one or two substituents selected from the group containing halogen, C, -C 6 - alkyl, C 1 -C g- alkoxy group, C, —C-alkylenedioxy group, trifluoromethyl, cyano-, nitro-, hydroxy-, < C 1 -C fi -alkylthio- or C ( ~ C 6 -alkanoylamino group or oxapolymethylene containing from 2 to 4 carbon atoms;
    R g is hydrogen, trifluoromethyl or C ^ Cg-alkyl, provided that when both R q and R b are alkyl, the total number of their carbon atoms is less than or equal to 8 or R fl and R fc together form a polymethylene containing from 2 to 7 carbon atoms;
    R c is an oxy group, C, -C g alkoxy or a C ^ C ^ alkanesulfonamido group;
    η is an integer equal to I or 2;
    A is ethylene or vinylene;
    Υ - polymethylene containing from 2 to 5 carbon atoms;
    B is a benzene ring unsubstituted or substituted by one or two substituents selected from the group consisting of halogen, C 1 -C b- alkyl, C, C 6 -alkoxy, hydroxy, trifluoromethyl or nitro, or their optically active forms, or, . When R c - hydroxy group, their physiologically acceptable salts with bases, characterized in that the aldehyde of General formula II
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1277893A3|1986-12-15|Method of producing 4-phenyl-1,3-dioxan-cis-5-ilalkenic acid derivatives or their optically active forms,or their physiologically acceptable salts with bases
    PL99931B1|1978-08-31|METHOD OF MAKING NEW PROSTAGLANDIN ANALOGS
    SU1480760A3|1989-05-15|Method of producing arythrodiol-5-yl-alkenic acid
    FR2642065A1|1990-07-27|BENZOCYCLOALCENYL DIHYDROXY ALKANOIC ACID DERIVATIVES, PREPARATION METHOD AND MEDICAMENTS CONTAINING SAME
    EP0201354B1|1990-09-19|2,4-diphenyl-1,3-dioxanes
    DK163579B|1992-03-16|ANALOGY PROCEDURE FOR THE PREPARATION OF CARBACYCLINE DERIVATIVES
    CA1258863A|1989-08-29|Cyclohexane derivatives
    US4704399A|1987-11-03|1,3-dioxan-4-ylalkenoic acids
    US4772625A|1988-09-20|1,3-dioxan-5-yl-hexenoic acids
    US4806563A|1989-02-21|N-[4-O-hydroxyphenyl-1,3-dioxan-5-ylhexenoyl]sulphonamides
    US4775684A|1988-10-04|1,3-dioxane ethers
    EP0246002B1|1991-11-27|Alkenamide derivatives
    EP0228887B1|1991-04-24|Dioxane hexenoic acids
    FR2693653A1|1994-01-21|Therapeutic compositions based on N- | amine derivatives.
    FR2581645A1|1986-11-14|DERIVATIVES OF OCTENOIC ACID
    同族专利:
    公开号 | 公开日
    AU1422383A|1983-11-17|
    IE831005L|1983-11-12|
    EP0094239A3|1984-12-12|
    CS333683A2|1985-09-17|
    AR240817A1|1991-02-28|
    PL140462B1|1987-04-30|
    AR240817A2|1991-02-28|
    DK211883D0|1983-05-11|
    GB8310407D0|1983-05-25|
    DD212515A5|1984-08-15|
    HU198705B|1989-11-28|
    PL140463B1|1987-04-30|
    ES528575A0|1986-10-16|
    JPH0378389B2|1991-12-13|
    NO162383B|1989-09-11|
    EP0094239B1|1987-07-15|
    KR880002001B1|1988-10-11|
    IL68628D0|1984-05-31|
    ZW10083A1|1984-11-28|
    HK17889A|1989-03-10|
    EP0094239A2|1983-11-16|
    PH21691A|1988-01-13|
    CS245783B2|1986-10-16|
    NO831679L|1983-11-14|
    CA1269109A|1990-05-15|
    CA1268771C|1990-05-08|
    US5166377A|1992-11-24|
    PL241920A1|1985-03-26|
    AU562056B2|1987-05-28|
    CY1453A|1989-07-21|
    DK211883A|1983-11-13|
    CS245795B2|1986-10-16|
    ES8700250A1|1986-10-16|
    KR840004739A|1984-10-24|
    DK163431C|1992-07-20|
    US4567197A|1986-01-28|
    ES528577A0|1986-06-16|
    MW1583A1|1985-02-13|
    DE3372483D1|1987-08-20|
    US4745198A|1988-05-17|
    FI831664A0|1983-05-12|
    SG57088G|1989-01-27|
    CA1268772A|1990-05-08|
    ES8608507A1|1986-06-16|
    JPS58222081A|1983-12-23|
    ES528576A0|1986-10-16|
    PT76684B|1986-01-14|
    PL250099A1|1985-07-02|
    FI80027C|1990-04-10|
    CA1258464A1|1989-08-15|
    DD219769A5|1985-03-13|
    PL250098A1|1985-07-02|
    FI80027B|1989-12-29|
    NZ204202A|1986-05-09|
    DK163431B|1992-03-02|
    ES8407038A1|1984-08-16|
    FI831664L|1983-11-13|
    AT28329T|1987-08-15|
    PT76684A|1983-06-01|
    CA1268771A|1990-05-08|
    ES522331A0|1984-08-16|
    KE3823A|1988-10-21|
    PL140274B1|1987-04-30|
    CS725784A2|1985-09-17|
    ES8700249A1|1986-10-16|
    IE55114B1|1990-06-06|
    GR78138B|1984-09-26|
    ZA833179B|1984-04-25|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2647727C2|2012-05-18|2018-03-19|Санофи|Benzo[1,3]dioxin derivatives and their use as lpar5 antagonists|US4243592A|1979-03-12|1981-01-06|The Upjohn Company|9,11-Dideoxy-10-oxa-TXB compounds|
    GB8310407D0|1982-05-12|1983-05-25|Ici Plc|1 3 - dioxan -5- ylalkenoic acids|
    GB8417314D0|1984-07-06|1984-08-08|Ici Plc|Carboxylic acid derivatives|GB8310407D0|1982-05-12|1983-05-25|Ici Plc|1 3 - dioxan -5- ylalkenoic acids|
    FR2551446B1|1983-08-31|1987-03-20|Elf Aquitaine|RESIN COMPOSITIONS HAVING IMPROVED IMPACT RESISTANCE CONTAINING A THERMOPLASTIC POLYMER, A SHOCK ADDTIVE OF THE GRAFT COPOLYMER TYPE, AND POSSIBLY OTHER ADDITIVES, AND CORRESPONDING GRAFT COPOLYMER, WITH THE CHARACTER OF SHOCK ADDITIVE|
    GB8330120D0|1983-11-11|1983-12-21|Ici Plc|Chemical process|
    GB8330097D0|1983-11-11|1983-12-21|Ici Plc|Cyclic ethers|
    GB8330094D0|1983-11-11|1983-12-21|Ici Plc|Diphenyl compounds|
    GB8417314D0|1984-07-06|1984-08-08|Ici Plc|Carboxylic acid derivatives|
    EP0201352B1|1985-05-10|1992-06-24|Imperial Chemical Industries Plc|Alkene derivatives|
    GB8511894D0|1985-05-10|1985-06-19|Ici Plc|Phenol derivatives|
    GB8511897D0|1985-05-10|1985-06-19|Ici Plc|Carboxylic acids|
    DK212786A|1985-05-10|1986-11-11|Ici Plc|1,3-DIOXANETHERE|
    GB8511891D0|1985-05-10|1985-06-19|Ici Plc|Alkenoic acids|
    GB8511892D0|1985-05-10|1985-06-19|Ici Plc|Fluoralkane derivatives|
    GB8511895D0|1985-05-10|1985-06-19|Ici Plc|Heterocyclic compounds|
    GB8511890D0|1985-05-10|1985-06-19|Ici Plc|Benzene derivatives|
    WO1987002983A1|1985-11-12|1987-05-21|Imperial Chemical Industries Plc|Amide derivatives|
    GB8531892D0|1985-12-30|1986-02-05|Ici Plc|Carboxylic acids|
    DE3603662A1|1986-02-06|1987-08-13|Basf Ag|ACETALIZED OR KETALIZED DIHYDROXYALDEHYDE, METHOD FOR THE PRODUCTION THEREOF AND SOLUTIONS CONTAINING THEM|
    GB8611174D0|1986-05-08|1986-06-18|Ici Plc|Amide derivatives|
    GB8626297D0|1986-11-04|1986-12-03|Ici Plc|Pharmaceutical compositions|
    GB8626296D0|1986-11-04|1986-12-03|Ici Plc|Therapeutic agents|
    GB8709794D0|1987-04-24|1987-05-28|Ici Plc|Heterocyclic acids|
    GB8901201D0|1988-02-16|1989-03-15|Ici Plc|Pyridine derivatives|
    US5248780A|1988-02-16|1993-09-28|Imperial Chemical Industries, Plc|Pyridyl substituted alkenoic acid derivatives|
    EP0346511A1|1988-06-15|1989-12-20|Fujisawa Pharmaceutical Co., Ltd.|Oxygen-containing hererocyclic compound, processes for their preparation and pharmaceutical compositions comprising them|
    IE81170B1|1988-10-21|2000-05-31|Zeneca Ltd|Pyridine derivatives|
    CN1034120C|1988-10-21|1997-02-26|曾尼卡有限公司|Pyridine derivatives|
    GB9021571D0|1990-10-04|1990-11-21|Ici Plc|Heterocyclic acids|
    US5925795A|1996-09-16|1999-07-20|Zeneca Limited|Processes for the preparation of aryl-β-diketones, arylpyrimidine ketones and crop protection intermediates|
    GB0413970D0|2004-06-22|2004-07-28|Syngenta Participations Ag|Chemical compounds|
    EP1976509B1|2006-01-18|2014-12-17|Evolva SA|Ppar modulators|
    CN101641009A|2007-01-18|2010-02-03|埃沃尔瓦公司|1 of replacement, 3-dioxane prodrug and application thereof|
    BRPI0806686A2|2007-01-18|2014-11-04|Evolva Sa|COMPOUNDS AND ITS USES, METHODS OF TREATMENT OR PREVENTION, PHARMACEUTICAL COMPOSITIONS AND CRYSTALLINE COMPOUND AND SOLVAT|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB8213702|1982-05-12|
    [返回顶部]